Edluar receives FDA approval

Edluar receives FDA approval 

The US Food and Drug Administration (FDA) has approved Edluar (formerly
Sublinox) for the short-term treatment of insomnia. The product contains the
well-known substance zolpidem and uses Orexo's patented sublingual tablet
formulation. The collaboration agreement with Orexo entitles them to a milestone
payment at FDA approval. That milestone is 5 MUSD based on the product
labelling. No further milestone payments for Edluar are expected to be due
Orexo. Product launch in the US is anticipated to start during 2nd half of 2009.


For more information contact:

Anders Larnholt, VP Investor Relations	tel. +46 709 458 878

MEDA AB (publ) is a leading international specialty pharma company. The company
specialises in marketing and pharmaceutical development in late clinical stage.
Acquisitions and long-term partnerships drive the company's strategy. Meda is
represented by its own organizations in about 40 countries. Meda's products are
sold in 120 countries worldwide. The Meda share is listed under Large Cap on the
Nasdaq OMX Nordic Stock Exchange Stockholm. Find out more, visit www.meda.se.